These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 34163726)

  • 1. Universal endogenous antibody recruiting nanobodies capable of triggering immune effectors for targeted cancer immunotherapy.
    Hong H; Li C; Gong L; Wang J; Li D; Shi J; Zhou Z; Huang Z; Wu Z
    Chem Sci; 2021 Feb; 12(12):4623-4630. PubMed ID: 34163726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Site-specific C-terminal dinitrophenylation to reconstitute the antibody Fc functions for nanobodies.
    Hong H; Zhou Z; Zhou K; Liu S; Guo Z; Wu Z
    Chem Sci; 2019 Oct; 10(40):9331-9338. PubMed ID: 32110296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of a CD70-Specific Fusion Nanobody with IgG Recruiting Capacity for Tumor Killing.
    Liu C; Li J; Hu Q; Xu X; Zhang X
    Int J Nanomedicine; 2023; 18():3325-3338. PubMed ID: 37361386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Full-length recombinant antibodies from
    Rashid MH
    MAbs; 2022; 14(1):2111748. PubMed ID: 36018829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV.
    Zhao G; He L; Sun S; Qiu H; Tai W; Chen J; Li J; Chen Y; Guo Y; Wang Y; Shang J; Ji K; Fan R; Du E; Jiang S; Li F; Du L; Zhou Y
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29950421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemical Synthesis of Antibody-Hapten Conjugates Capable of Recruiting the Endogenous Antibody to Magnify the Fc Effector Immunity of Antibody for Cancer Immunotherapy.
    Zhou K; Hong H; Lin H; Gong L; Li D; Shi J; Zhou Z; Xu F; Wu Z
    J Med Chem; 2022 Jan; 65(1):323-332. PubMed ID: 34962121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemoenzymatic Synthesis of a Rhamnose-Functionalized Bispecific Nanobody as a Bispecific Antibody Mimic for Cancer Immunotherapy.
    Hong H; Lin H; Li D; Gong L; Zhou K; Li Y; Yu H; Zhao K; Shi J; Zhou Z; Huang Z; Wu Z
    Angew Chem Int Ed Engl; 2022 Sep; 61(38):e202208773. PubMed ID: 35891606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics.
    Bannas P; Hambach J; Koch-Nolte F
    Front Immunol; 2017; 8():1603. PubMed ID: 29213270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer.
    Desroys du Roure P; Lajoie L; Mallavialle A; Alcaraz LB; Mansouri H; Fenou L; Garambois V; Rubio L; David T; Coenon L; Boissière-Michot F; Chateau MC; Ngo G; Jarlier M; Villalba M; Martineau P; Laurent-Matha V; Roger P; Guiu S; Chardès T; Gros L; Liaudet-Coopman E
    J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38290768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth.
    Roovers RC; Vosjan MJ; Laeremans T; el Khoulati R; de Bruin RC; Ferguson KM; Verkleij AJ; van Dongen GA; van Bergen en Henegouwen PM
    Int J Cancer; 2011 Oct; 129(8):2013-24. PubMed ID: 21520037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging applications of nanobodies in cancer therapy.
    Awad RM; Meeus F; Ceuppens H; Ertveldt T; Hanssens H; Lecocq Q; Mateusiak L; Zeven K; Valenta H; De Groof TWM; De Vlaeminck Y; Krasniqi A; De Veirman K; Goyvaerts C; D'Huyvetter M; Hernot S; Devoogdt N; Breckpot K
    Int Rev Cell Mol Biol; 2022; 369():143-199. PubMed ID: 35777863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanobody-based CTLA4 inhibitors for immune checkpoint blockade therapy of canine cancer patients.
    Marable J; Ruiz D; Jaiswal AK; Bhattacharya R; Pantazes R; Agarwal P; Suryawanshi AS; Bedi D; Mishra A; Smith BF; Sandey M
    Sci Rep; 2021 Oct; 11(1):20763. PubMed ID: 34675296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanobodies in cell-mediated immunotherapy: On the road to fight cancer.
    Maali A; Gholizadeh M; Feghhi-Najafabadi S; Noei A; Seyed-Motahari SS; Mansoori S; Sharifzadeh Z
    Front Immunol; 2023; 14():1012841. PubMed ID: 36761751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanobody-targeted photodynamic therapy induces significant tumor regression of trastuzumab-resistant HER2-positive breast cancer, after a single treatment session.
    Deken MM; Kijanka MM; Beltrán Hernández I; Slooter MD; de Bruijn HS; van Diest PJ; van Bergen En Henegouwen PMP; Lowik CWGM; Robinson DJ; Vahrmeijer AL; Oliveira S
    J Control Release; 2020 Jul; 323():269-281. PubMed ID: 32330574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteolytic single hinge cleavage of pertuzumab impairs its Fc effector function and antitumor activity in vitro and in vivo.
    Hsiao HC; Fan X; Jordan RE; Zhang N; An Z
    Breast Cancer Res; 2018 Jun; 20(1):43. PubMed ID: 29859099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High affinity nanobodies against human epidermal growth factor receptor selected on cells by E. coli display.
    Salema V; Mañas C; Cerdán L; Piñero-Lambea C; Marín E; Roovers RC; Van Bergen En Henegouwen PM; Fernández LÁ
    MAbs; 2016 Oct; 8(7):1286-1301. PubMed ID: 27472381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Versatile Application of Nanobodies for Food Allergen Detection and Allergy Immunotherapy.
    Hu Y; Wang Y; Lin J; Wu S; Muyldermans S; Wang S
    J Agric Food Chem; 2022 Jul; 70(29):8901-8912. PubMed ID: 35820160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening and antitumor effect of an anti‑CTLA‑4 nanobody.
    Wan R; Liu A; Hou X; Lai Z; Li J; Yang N; Tan J; Mo F; Hu Z; Yang X; Zhao Y; Lu X
    Oncol Rep; 2018 Feb; 39(2):511-518. PubMed ID: 29207143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way.
    Yu X; Long Y; Chen B; Tong Y; Shan M; Jia X; Hu C; Liu M; Zhou J; Tang F; Lu H; Chen R; Xu P; Huang W; Ren J; Wan Y; Sun J; Li J; Jin G; Gong L
    J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36253000
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.